

**Contact:**

Loraine V. Upham

[Lori@CureDM.com](mailto:Lori@CureDM.com)

(505-515-1947)

## CureDM Announces Results of Phase 1b Study in Type 2 Diabetes Patients

Wilmington, DE – March 20, 2016 – CureDM announces completion of the Phase 1b Study entitled “A Randomized, Double-blind, Placebo-controlled Study of the Effect of 49 Days of Treatment With Repeated Subcutaneous Doses of HIP2B to Assess Safety, Tolerability and Measures of Islet  $\beta$ -cell Function in Subjects With Type 2 Diabetes Mellitus Treated With Metformin.” Based on clinical analysis of safety parameters, HIP2B was well tolerated and there are no safety issues that would preclude further development of HIP2B. Statistically significant effects in Insulin Secretion in response to GGI, fasting c-Peptide, and pre-hepatic Insulin Secretion Rate were seen as secondary endpoints.

“We are very pleased to present these results in collaboration with our Clinical Research partners at Profil Institute at the 2016 ADA conference in New Orleans,” states Loraine Upham, co-founder of CureDM. We are excited to plan the next study in a larger cohort of type 2 diabetes patients or a very targeted specific type 1 diabetes patient population. The CureDM drug, HIP2B is a human derived peptide therapeutic that stimulates proteomic pathways that lead to islet neogenesis that can restore islet mass by creating new, healthy islets.

### **About CureDM**

CureDM is a biopharmaceutical company focused on the discovery and development of new therapeutics that prevent, ameliorate, or reverse diseases of metabolism. CureDM was co-founded by a molecular biologist and two endocrinologists who experienced the unmet medical need in diabetes patients on a daily basis, which provided the motivation for the discovery of HIP2B. For more information about CureDM, visit [www.curedm.com](http://www.curedm.com).

XXXXXX